Literature DB >> 17968609

Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice.

A Cano1, S Dapía, I Noguera, B Pineda, C Hermenegildo, R del Val, J R Caeiro, M A García-Pérez.   

Abstract

UNLABELLED: This study assessed the effect of estradiol, raloxifene and genistein on the preservation of bone 3D-microarchitecture and volumetric bone mineral density (vBMD) in the ovariectomized mouse model. Our results indicated that raloxifene was more effective in preserving bone ovariectomized-induced changes, the advantage being concentrated in both bone microarchitecture and vBMD.
INTRODUCTION: This study assessed the effect of different estrogen receptor (ER) agonists on the preservation of bone 3D-microarchitecture and volumetric bone mineral density (vBMD) in the ovariectomized (OVX) mouse model.
METHODS: Twelve-week-old female C57BL/6 mice were randomly assigned to one of five groups: (1) SHAM-operated + vehicle; (2) OVX + vehicle; (3) OVX + 17beta-estradiol (5 microg/kg); (4) OVX + raloxifene (1 mg/kg); (5) OVX + genistein (25 mg/kg), during 4-weeks. Bone microarchitecture and trabecular, cortical and total vBMD of distal femur were imaged by ex vivo microcomputed tomography (micro-CT).
RESULTS: Ovariectomy produced a global deterioration involving both trabecular and cortical 3D-microarchitecture and vBMD. Raloxifene maintained both microarchitecture and vBMD, whereas estradiol prevented deterioration of some microstructural parameters, such as trabecular thickness (Tb.Th), trabecular bone pattern factor (Tb.Pf), and cortical periosteal perimeter (Ct.Pe.Pm), but did not completely block the loss in vBMD. Mice treated with genistein exhibited the less favourable profile in both vBMD and microstructural parameters preserving only cross-sectional bone area (B.Ar) and Ct.Pe.Pm in cortical bone.
CONCLUSION: Our data indicate that, at the selected doses, raloxifene was more effective in preserving bone OVX-induced changes than either estradiol or genistein, the advantage being concentrated in both bone microarchitecture and vBMD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17968609     DOI: 10.1007/s00198-007-0498-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  37 in total

1.  Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens.

Authors:  J An; C Tzagarakis-Foster; T C Scharschmidt; N Lomri; D C Leitman
Journal:  J Biol Chem       Date:  2001-02-21       Impact factor: 5.157

Review 2.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

Authors:  B Lawrence Riggs; Lynn C Hartmann
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

3.  Trabecular bone pattern factor--a new parameter for simple quantification of bone microarchitecture.

Authors:  M Hahn; M Vogel; M Pompesius-Kempa; G Delling
Journal:  Bone       Date:  1992       Impact factor: 4.398

4.  Comparative effects of estradiol, raloxifene, and genistein on the uterus of ovariectomized mice.

Authors:  Miguel Angel García-Pérez; Rosa Noguera; Raquel del Val; Inmaculada Noguera; Carlos Hermenegildo; Antonio Cano
Journal:  Fertil Steril       Date:  2006-09-11       Impact factor: 7.329

5.  Strength of cancellous bone trabecular tissue from normal, ovariectomized and drug-treated rats over the course of ageing.

Authors:  L M McNamara; A G H Ederveen; C G Lyons; C Price; M B Schaffler; H Weinans; P J Prendergast
Journal:  Bone       Date:  2006-04-27       Impact factor: 4.398

6.  Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice.

Authors:  M C Erlandsson; C A Jonsson; M K Lindberg; C Ohlsson; H Carlsten
Journal:  J Endocrinol       Date:  2002-11       Impact factor: 4.286

7.  Estrogen receptor agonists and immune system in ovariectomized mice.

Authors:  M A García-Pérez; R Del Val; I Noguera; C Hermenegildo; B Pineda; A Martinez-Romero; A Cano
Journal:  Int J Immunopathol Pharmacol       Date:  2006 Oct-Dec       Impact factor: 3.219

8.  The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats.

Authors:  P Fanti; M C Monier-Faugere; Z Geng; J Schmidt; P E Morris; D Cohen; H H Malluche
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

Review 9.  A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.

Authors:  B L Riggs; S Khosla; L J Melton
Journal:  J Bone Miner Res       Date:  1998-05       Impact factor: 6.741

10.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

View more
  18 in total

1.  Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.

Authors:  Yu Shao; Selene Hernandez-Buquer; Paul Childress; Keith R Stayrook; Marta B Alvarez; Hannah Davis; Lilian I Plotkin; Yongzheng He; Keith W Condon; David B Burr; Stuart J Warden; Alexander G Robling; Feng-Chun Yang; Ronald C Wek; Matthew R Allen; Joseph P Bidwell
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

2.  Differences in femoral neck geometry associated with age and ethnicity.

Authors:  K M Kim; J K Brown; K J Kim; H S Choi; H N Kim; Y Rhee; S-K Lim
Journal:  Osteoporos Int       Date:  2010-10-26       Impact factor: 4.507

3.  Effects of PEMFs on Osx, Ocn, TRAP, and CTSK gene expression in postmenopausal osteoporosis model mice.

Authors:  Zhen-Hua Song; Wei Xie; Si-Yi Zhu; Jin-Jing Pan; Lu-Yao Zhou; Cheng-Qi He
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

4.  Hydrolyzed collagen improves bone status and prevents bone loss in ovariectomized C3H/HeN mice.

Authors:  F Guillerminet; V Fabien-Soulé; P C Even; D Tomé; C-L Benhamou; C Roux; A Blais
Journal:  Osteoporos Int       Date:  2011-09-17       Impact factor: 4.507

5.  Genistein, a phytoestrogen, improves total cholesterol, and Synergy, a prebiotic, improves calcium utilization, but there were no synergistic effects.

Authors:  LeeCole L Legette; Wang-Hee Lee; Berdine R Martin; Jon A Story; Ali Arabshahi; Stephen Barnes; Connie M Weaver
Journal:  Menopause       Date:  2011-08       Impact factor: 2.953

6.  The stronger sex, until menopause: understanding the impact of estrogen loss on heart function.

Authors:  Cassandra K Conway-O'Donnell; Naomi C Chesler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-06-03       Impact factor: 5.125

7.  Selective estrogen receptor modulation prevents scoliotic curve progression: radiologic and histomorphometric study on a bipedal C57Bl6 mice model.

Authors:  Gokhan Demirkiran; Ozgur Dede; Nadir Yalcin; Ibrahim Akel; Ralph Marcucio; Emre Acaroglu
Journal:  Eur Spine J       Date:  2013-10-18       Impact factor: 3.134

8.  Time and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model.

Authors:  Nadia Mohd Effendy; Shahrum Abdullah; Mohd Faridz Mod Yunoh; Ahmad Nazrun Shuid
Journal:  BMC Complement Altern Med       Date:  2015-03-12       Impact factor: 3.659

9.  Differences in osteogenic and apoptotic genes between osteoporotic and osteoarthritic patients.

Authors:  Mercè Giner; Ma José Montoya; Ma Angeles Vázquez; Cristina Miranda; Ramón Pérez-Cano
Journal:  BMC Musculoskelet Disord       Date:  2013-01-25       Impact factor: 2.362

10.  Greater Skeletal Gains in Ovary Intact Rats at Maturity Are Achieved by Supplementing a Standardized Extract of Butea monosperma Stem Bark that Confers Better Bone Conserving Effect following Ovariectomy and Concurrent Treatment Withdrawal.

Authors:  Kamini Srivastava; Kainat Khan; Abdul M Tyagi; Mohd P Khan; Dinesh K Yadav; Ritu Trivedi; Rakesh Maurya; Divya Singh; Naibedya Chattopadhyay
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.